This positioning suggests that apoB may serve as a clinically meaningful biomarker for risk stratification, bridging the gap between high-risk thresholds established by ADA/ACC and moderate-risk thresholds outlined in ATP III, as both of them have two or more risk factors with no previous history of diabetes or CAD. This evidence concerns the gene APOB and coronary artery disorder.